French biotech company wants to challenge Novo and Lilly: "They are not unreachable"

Changed dynamics in the insulin market mean Novo Nordisk and Eli Lilly are not as invincible as in the past, says a director from Adocia. The French biotech company aims to take on the giants - and also compete with Zealand Pharma in another segment of the diabetes market.

Photo: /Ritzau Scanpix/Asger Ladefoged

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles